Rechercher
MENU
Primary Menu
Accueil
Présentation de FranceCoag
Qui sommes-nous ?
Projet FranceCoag
Gouvernances
Aspects réglementaires
Centres Partenaires
Conventions
Maladies rares hemorragiques
Hémophilies
Maladie de Willebrand
Pathologies plaquettaires
Autres déficits rares
Bilans d’activité
Newsletter
Recherches scientifiques
Projets en cours
Projets finalisés
Publications scientifiques
Communications écrites et orales
Fiche de saisine – Accès aux données FranceCoag
Financeurs
Espace pro
Demande de création de compte
Connexion site privé FranceCoag
Accueil
Publications scientifiques
Publications scientifiques
2025
Rugeri L et al : Gynecological and obstetric outcome in the French cohort of women with Factor XIII deficiency
2023
Nguyen A et al : Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): A multicentric French national observational cross-sectional study based on the FranceCoag registry
2022
Resseguier N et al : Occupational integration of adults with severe haemophilia (INTHEMO): A study based on the FranceCoag registry
2021
Saultier P et al: Compliance with Early Long-Term Prophylaxis Guidelines for Severe Hemophilia A
2020
Bouttefroy S et al : Congenital factor XIII deficiency: comprehensive overview of the FranceCoag cohort
2020
Row C et al : Abnormal Bleeding Phenotype in Mild Hemophilia B Patients with the p.Ile112Thr Variation on the Gene for Factor IX
2019
Calvez T et al : Recombinant Factor VIII Products and Inhibitor Development in Previously Untreated Boys With Severe Hemophilia A
2019
Volkers A et al : Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies
2019
Iorio A et al : Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries
2018
Resseguier N et al : Determinants of Adherence and Consequences of the Transition From Adolescence to Adulthood Among Young People With Severe Haemophilia (TRANSHEMO): Study Protocol for a Multicentric French National Observational Cross-Sectional Study
2018
Doncarli A et al : FranceCoag: A 22-year Prospective Follow-Up of the National French Cohort of Patients With Inherited Bleeding Disorders
2015
Calvez T et al : Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product
2013
Meunier S et al : Use of clinical practice guidelines on long-term prophylaxis in severe hemophilia in France: a retrospective audit
2010
Chambost H et al : Epidemiology of Hereditary Bleeding Disorders: Input of FranceCoag Network
2007
Chambost H et al : Implementation of a hepatitis A prevention policy in haemophiliacs: results from the French cohort
2002
Chambost H et al : What Factors Influence the Age at Diagnosis of Hemophilia? Results of the French Hemophilia Cohort
2002
Gaboulaud V et al : Prevalence of IgG Antibodies to Human Parvovirus B19 in Haemophilia Children Treated With Recombinant Factor (F)VIII Only or With at Least One Plasma-Derived FVIII or FIX Concentrate: Results From the French Haemophilia Cohort
2001
Calvez T et al : The French Haemophilia Cohort: Rationale and Organization of a Long-Term National Pharmacosurveillance System